Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1

Project Information

ImmunoNet

Grant agreement ID: 190109071

DOI 10.3030/190109071

EC signature date 31 August 2022

Start date 1 September 2022

End date 31 December 2025

Funded under

• The European Innovation Council (EIC)

Total cost € 8 327 233,75

EU contribution € 2 500 000,00

Coordinated by

NETRIS PHARMA SAS
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (3)

Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

Author(s): Cassier P.A., et al.
Published in: Nature, Issue 620, 2023, ISSN 0028-0836
Publisher: Springer Nature
DOI: 10.1038/s41586-023-06367-z

Pharmacological targeting of netrin-1 inhibits EMT in cancer

Author(s): Lengrand, J. et al
Published in: Nature, Issue 620, 2023, ISSN 0028-0836
Publisher: Springer-Nature
DOI: 10.1038/s41586-023-06372-2

Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling

Author(s): Crissy Dudgeon, Anthony Casabianca, Chris Harris, Charline Ogier, Mélanie Bellina, Stephany Fiore, Agnes Bernet, Benjamin Ducarouge, David Goldschneider, Xiaoyang Su, Jason Pitarresi, Aram Hezel, Subhajyoti De, Wade Narrow, Fady Soliman, Cory Shields, Debora Barbosa Vendramini-Costa, Orjola Prela, Lan Wang, Igor Astsaturov, Patrick Mehlen, Darren R. Carpizo
Published in: Cell Reports, Issue 42, 2023, ISSN 2211-1247
Publisher: Elsevier BV
DOI: 10.1016/j.celrep.2023.113369